



AT CAPITAL DAILY MARKET UPDATE – October 8, 2017

Overview:

The DSEX closed at 6,205.5 points, up by 3.2 points. Total turnover was worth BDT 10.54 bn. Prices of 117 issues were increased whereas that of 181 issues were declined, and the price of the rests were remained unchanged.

Index Movements:

INDEX	VALUE	DAY CH(%)	MTD(%)	YTD(%)
DSEX	6,205.5	+0.1%	+1.8%	+23.2%
DSES	1,354.7	+0.4%	+1.5%	+13.7%
DS30	2,215.2	+0.6%	+1.8%	+22.3%

MARKET STAT		TODAY	LAST DAY	CHANGE(%)
MARKET CAP (Equity)	BDT MM	3,510,315.0	3,507,895.2	+0.1%
	USD MM	43,878.9	43,848.7	+0.1%
TURNOVER	BDT MM	10,542.5	10,585.0	(0.4%)
	USD MM	131.8	132.3	(0.4%)
VOLUME	MM SHARES	343.5	348.5	(1.4%)

Market commentary:

Large-cap scrips led the market today. DSEX, the broad index, initiated the session with an upbeat. However, the broad index fell sharply during the first trading hour. DSEX experienced range bound trade till the end of the session. Market closed the session at 6,205.5, up by 3.2 points.

Losers outnumbered gainers today Losers to Gainers ratio was 1.5:1


Turnover decreased by 0.4% to BDT 10.54 bn. Bank sector dominated the turnover chart - the sector accounted for 48.2% of total turnover, followed by NBF1 (15.1%) and, Pharma sector (6.3%). Banks' turnover fell ~11.0% whereas both NBF1's and Pharma's surged by 68.3% and 29.1% respectively.

Most of prominent sectors, except NBF1, Food & Allied and Pharma, underperformed the market today.


Islami Bank topped the turnover chart today with the turnover of BDT 619mn - the stock gained 4.8%.

TOP 10 GAINERS			TOP 10 LOSERS		
TRADING CODE	CLOSEP	%CHANGE	TRADING CODE	CLOSEP	%CHANGE
PLFSL	15.3	+2.0%	UNIONCAP	21.0	(3.7%)
ILFSL	23.1	+1.8%	PREMIERLEA	17.6	(2.2%)
MIDASFIN	38	+1.6%	BAYLEASING	27.2	(2.2%)
ICB	186.1	+1.1%	NHFIL	50.9	(2.1%)
PHOENIXFIN	35.6	+0.6%	LANKABAFIN	62.9	(1.7%)
BDFINANCE	20.4	+0.5%	ISLAMICFIN	23.4	(1.7%)
IDLC	89.6	+0.3%	UNITEDFIN	23.4	(1.7%)
PRIMEFIN	13.6	+0.0%	GSPFINANCE	29.7	(1.7%)
FIRSTFIN	14.6	+0.0%	FASFIN	18.8	(1.1%)
DBH	125.5	(0.1%)	BIFC	11.5	(0.9%)

Sector Movement in DSE (Oct 08- Oct 05)



Last 1 Month DSEX





News:

BB jacks up dollar sales to keep exchange rate stable

Bangladesh Bank has already surpassed its fiscal 2016-17's sales figure of US dollar in the first three months of the current fiscal year as it scrambles to prevent the slide of the taka against the greenback. "The local currency would have depreciated to Tk 85 against a dollar if the central bank had not intervened," said a BB official. Falling remittance and a surge in imports have created a scarcity of the US dollar, which is mostly used in international transactions and, as a result, the world's primary reserve currency. From July 1 to October 5, the central bank has sold \$199 million to banks. Last fiscal year, it sold \$175 million and purchased \$1.93 billion. On October 4, the inter-bank exchange rate of the US dollar stood at Tk 80.80, up from Tk 80.60 on July 2. An importer has to pay at least Tk 1 more than the inter-bank rate for making their payments. "Some banks had no option to purchase dollar from the central bank," said Syed Mahbubur Rahman, managing director of Dhaka Bank. The reason is that the import growth has outstripped the export growth by a wide margin, he said. In the first two months of the fiscal year, letters of credit settlement, which gives a measure of the import growth, soared 31 percent year-on-year to \$9.41 billion. The downward trend in remittance inflow has also created a greenback shortage, Rahman added. In September, migrant workers sent home \$853.73 million, down 19.20 percent from a year earlier. Kazi Masihur Rahman, managing director of Mercantile Bank, echoed the same.

<http://www.thedailystar.net/business/bb-jacks-dollar-sales-keep-exchange-rate-stable-1473145>

Beximco may buy majority stake in Nuvista Pharma

Beximco Pharmaceuticals has announced it may buy 85.22 percent share in Nuvista Pharma to strengthen its position in hormones and steroids segments. Beximco Pharmaceuticals entered into a non-binding memorandum of understanding with the hormones and steroid drugs-maker at a programme in Dhaka on Thursday. Nazmul Hassan, managing director of Beximco Pharma, and Akhter Matin Chaudhury, chairman of Nuvista Pharma, signed the primary deal. The proposed acquisition remains subject to due diligence and negotiation and completion of a definitive sale and purchase agreement. It is expected that the proposed acquisition will be completed by the end of December, said Beximco Pharma in a statement. "The directors believe that the proposed acquisition will, if completed, accelerate revenue growth and improve the earning potential for Beximco Pharma," according to the statement. Hassan said: "We believe that the proposed acquisition would be the first in our company's history and will serve as a strong foundation for sustainable growth in the future." "In our view, Nuvista Pharma is a good strategic fit for Beximco Pharma as their strong position in hormones and steroids, with a unique portfolio of 50 generics, complements our existing product range." Nuvista Pharma, formerly Organon (Bangladesh) Ltd, was a subsidiary of the Netherlands-based Organon International. It was sold out to the current Bangladeshi management in 2006. The company has been operating in Bangladesh since 1964, with a local manufacturing plant in Tongi. It has a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme. Currently Nuvista Pharma is the 21st largest supplier to the market by volume, according to the QuintilesIMS second quarter data of the retail pharma market in Bangladesh this year. Founded in 1976, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients.

<http://www.thedailystar.net/business/beximco-may-buy-majority-stake-nuvista-pharma-1473133>